Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:26 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
NCT00430040 · University at Buffalo · PHASE4 · terminated · last registry update 2024-04-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, University at Buffalo |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ACE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-17Also stopped (withdrawn): Nova Scotia Health Authority, Intralesional enalaprilat injection (NCT05259137)
- 2024-11-06Also stopped (terminated): University of Alberta, labetalol/hydralazine/enalapril (NCT02281838)
- 2024-07-16Results posted on the registry: University of Wisconsin, Madison, Anti-Hypertensive (NCT05479097)
- 2024-07-16Results posted on the registry: University of Maryland, Baltimore, pravastatin and chenodeoxycholic acid, after metformin and placebo + valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo (NCT04640571)
- 2024-02-28Results posted on the registry: Penn State University, Captopril Pill + Enalapril Pill (NCT03179163)
- 2024-02-28Also stopped (terminated): Penn State University, Captopril Pill + Enalapril Pill (NCT03179163)
- 2024-02-20Also stopped (terminated): Istituto Auxologico Italiano, enalapril tablets + placebo tablets (NCT00456963)
- 2024-01-08Results posted on the registry: Novartis Pharmaceuticals, LCZ696 + Enalapril matching placebo (NCT03917459)
- 2023-12-08Results posted on the registry: Novartis Pharmaceuticals, LCZ696 + Enalapril (NCT02468232)
- 2023-10-24Also stopped (terminated): Novartis, Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 + Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (NCT00170950)
- 2023-10-18Also stopped (terminated): Institut de Recherches Internationales Servier, Atorvastatin/Perindopril + Atorvastatin (NCT04591808)
- 2023-04-20Phase 3 first posted: Institut de Recherches Internationales Servier, Fixed [Per/Ind/Aml] + Free [Per/Ind + Aml] (NCT05820880)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision